Details for New Drug Application (NDA): 021024
✉ Email this page to a colleague
NDA 021024 describes PRIFTIN, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from one supplier. Additional details are available on the PRIFTIN profile page.
The generic ingredient in PRIFTIN is rifapentine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the rifapentine profile page.
The generic ingredient in PRIFTIN is rifapentine. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the rifapentine profile page.
Summary for 021024
| Tradename: | PRIFTIN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | rifapentine |
| Patents: | 0 |
Suppliers and Packaging for NDA: 021024
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PRIFTIN | rifapentine | TABLET;ORAL | 021024 | NDA | sanofi-aventis U.S. LLC | 0088-2102 | 0088-2102-24 | 3 BLISTER PACK in 1 CARTON (0088-2102-24) / 8 TABLET, FILM COATED in 1 BLISTER PACK (0088-2102-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Jun 22, 1998 | TE: | AB | RLD: | Yes | ||||
Complete Access Available with Subscription
